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Abstract  
In frail older adults, low blood pressure (BP) might be associated with worse health 
outcomes and hypertension management in this population is highly debated. Using data 
from a population-based study of older adults, we assessed the association between frailty 
and BP. We used data collected between 2014 and 2016 from 3157 participants aged 
between 67 and 80 years in the Lausanne cohort Lc65+. BP was measured three times at 
one visit and frailty status was assessed based on Fried’s phenotype model. We analyzed 
the cross-sectional association between BP and frailty by computing mean systolic and 
diastolic BP stratified by sex, age, and frailty and by fitting regression models. The average 
age of the participants was 73.3 (standard deviation (SD): 4.1) years and 59.1% were 
women. 34.1% were pre-frail, and 3.3% were frail. Mean BP was 135.1/76.3 mmHg (SD 
18.5/11.0). Age- and sex-adjusted systolic BP was on average lower by 2.8 mmHg (95% 
confidence interval (CI): 1.4 to 4.2) and 6.7 mmHg (95% CI: 3.2 to 10.3) among pre-frail 
and frail compared to non-frail participants. Similar differences in mean diastolic BP 
across frailty status were found. Upon adjustment for antihypertensive treatment, the 
associations between frailty status and BP did not change substantially. Frail individuals 
had a substantially lower BP compared with non-frail older adults. Because low BP could 
be detrimental among frail older patients, our findings raise questions about hypertension 
management in this population and stress the need for additional evidence.  
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Introduction 
Lowering blood pressure (BP) is known to be beneficial in middle-aged adults, but recent 
research suggests that the benefit is questionable in older adults depending on their health 
status.1,2 Numerous trials have shown that lowering BP decreases the risk of cardiovascular 
disease (CVD) and mortality in middle-aged adults.3-6 In older adults, however, the 
evidence is scarce. While two trials including participants aged 75 or 80 years and over 
have shown that lowering BP reduced all-cause mortality and cardiovascular mortality7,8, 
several cohort studies have shown that older individuals with relatively low BP had higher 
mortality rates and worse physical and cognitive abilities compared to older individuals 
with higher BP.9-11 Hence, how to manage high BP among older adults remains highly 
debated, including in recent major guidelines.4,5 
  
In older adults, frailty may modify the relationship between BP and health outcomes.1,12,13 
Frailty is a multidimensional geriatric syndrome characterized by increased vulnerability 
and loss of adaptability to stress.14-16 It is associated with an increased risk of falls, 
delirium, disability and mortality.15,17 In a cohort study, van Hateren et al. showed that frail 
participants with high BP had lower mortality rates compared to frail participants with low 
BP.13 In another cohort study, Odden et al. showed that fast walking participants – 
considered as non-frail – with high BP had higher cardiovascular mortality rates compared 
to those with low BP; among slow walking participants – considered as frail – there was no 
difference in cardiovascular mortality rates across levels of BP.12 This suggests that a 
relatively low BP might be not beneficial and may even be detrimental in frail older adults.  
 
At the population level, the relationship between frailty, BP, and antihypertensive 
treatment remains poorly described.1 Using data from a population-based study16, we 
assessed the cross-sectional association between BP and frailty in individuals aged 
between 67 and 80 years. 
 
Methods 
Population 
We analyzed data from participants in the Lausanne cohort Lc65+, a population-based 
study of community-dwelling older adults. The Lc65+ was designed primarily to 
investigate the determinants, evolution, and outcomes of frailty.16 A total of 4731 
randomly selected community-dwelling residents of the city of Lausanne, Switzerland, 
were recruited at age 65 to 70 years in three waves at three different time points: sample 1 
(C1) in 2004, sample 2 (C2) in 2009 and sample 3 (C3) in 2014.18 Follow up is ongoing. 
Individuals were excluded if they were living in an institution or if they were unable to 
respond by themselves to questionnaires due to advanced dementia.  
 
Data collection 
Data was collected by means of self-administered mailed questionnaires, in-person 
interviews, and anthropometric measurements. Performance tests were conducted by 
trained research assistants at the study center, and, in some cases, at participants’ homes. 
For this analysis, we used data collected at baseline and at the most recent data collection 
for the 3 samples. The most recent data collection for the samples C1, C2, and C3 took 
place in 2014, 2016, and 2015, respectively. Details of time points of data collection for 
each variable included in the analyses are given in Table S1 in the supplementary digital 
content files. 
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Blood pressure measurement and definition of hypertension 
BP was measured following a standardized protocol kept identical across years in the three 
samples. Measures were made at the study center by trained medical research assistants 
using a clinically validated oscillometric automated device (Omron® 907 (HEM-907-E) 
digital automatic blood pressure monitor).19,20 In case of heart rhythm abnormalities, BP 
was measured using the auscultatory method with an Erkameter 3000® mercury 
tensiometer and a Duophon® or a Littmann® stethoscope. After 10 to 20 minutes of rest in 
a sitting position, BP was measured three times at 5 to 10 minutes intervals with a cuff size 
adapted to the participant’s arm circumference. Three cuff sizes were available: 17-22cm 
(HEM-CS19) for arm circumference less than 22 cm, 22-32 cm (HEM-CR19) for arm 
circumference between 22 and 32 cm, and 32-42 cm (HEM-CL19) for arm circumference 
33 cm and larger. BP was measured on the left arm. During the measurement, the 
participant was relaxed, sitting comfortably with his or her back supported, left arm resting 
on a support at level of the heart, and with the palm of the hand up.16  
 
Participants were classified as hypertensive (self-reported) if they answered “yes” to 
following questions: “Has a doctor ever told you that you have too high a blood pressure 
(hypertension)” or “Are you currently taking any medication to lower your blood pressure 
(hypertension) at least once a week?”. We have also explored further definitions of 
hypertension, respectively elevated BP by computing the number of participants with 
BP≥140/90 mmHg and the number of participants with BP≥140/90 mmHg OR self-
reported antihypertensive use. 
 
Frailty definition and measurement 
Frailty was assessed according to Fried’s phenotype model following a standardized 
procedure kept identical across years in the three samples.16,21 Fried’s phenotype model is 
based on five characteristics, that is, shrinking, exhaustion, weakness, slowness, and low 
activity. Shrinking was identified if the participant reported any unintentional weight loss 
in the prior year. Exhaustion was identified if a participant answered “a lot”, as compared 
to “not at all” or “a little”, to the question “did you have feelings of generalized weakness, 
weariness, lack of energy in the last four weeks?”. Weakness was identified if the highest 
value of three measures of grip strength was considered as low. Low grip strength was 
identified when participants’ measures were below certain sex- and body mass index-
specific cut-off values, as defined in the Cardiovascular Health study.21 Grip strength was 
measured on the right hand with a DHD-3 Digital Hand Dynamometer SAEHAN® 
Baseline® hydraulic dynamometer.22 Walking speed was measured at the study center and 
slowness was identified if the participant had a low walking speed over 20 meters. Low 
walking speed was identified when participants’ measures were below certain sex- and 
height-specific cut-off values, as defined in the Cardiovascular Health study.21 In some 
cases slowness was imputed based on the judgement of the research assistant following a 
decision algorithm. Briefly, the decision algorithm included 3 criteria: the use of walking 
aids, the opinion of a medical assistant on whether the participant’s gait speed was slowed 
down, difficult or impossible, and the participant’s performance in getting up from a chair. 
Low activity was identified if the participant reported less than 20 minutes of sport activity 
once a week and less than 30 cumulated minutes of walking per day 3 times a week and 
avoiding to climb stairs or carrying light loads in daily activities. Participants were 
classified as non-frail, pre-frail, or frail if they had none, one to two, or three to five of 
these characteristics, respectively.16 
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Assessment of other characteristics 
Hypercholesterolemia was defined if participants reported taking cholesterol-lowering 
medication or having been diagnosed with high cholesterol by a physician. Diabetes was 
defined if participants reported taking medication for diabetes or having been diagnosed 
with diabetes by a physician. History of CVD was defined if participants reported having 
been diagnosed with coronary heart disease, stroke, heart insufficiency, cardiomyopathy, 
heart valve disease, or other cardiopathy, or if they reported taking medication for the 
heart. Participants were interviewed about the presence of the following chronic diseases: 
arthrosis, Alzheimer’s disease, asthma, cancer, heart failure, coronary heart disease, 
chronic pulmonary disease, Parkinson’s disease, ulcer, HIV, osteoporosis, hypertension, 
hypercholesterolemia, and diabetes. Functional status was assessed using Katz' basic 
activities of daily living (BADL) and Lawton’s instrumental activities of daily living 
(IADL).23,24 To assess BADL, participants were asked if they had “no difficulties”, 
“difficulties but not receiving help”, or “difficulties and receiving help” with following 
activities: taking a bath or a shower, eating, getting in and out of bed or sofa, dressing, and 
using the toilet. To assess IADL, participants were asked if they had “no difficulties”, 
“difficulties but not receiving help”, or “difficulties and receiving help” with following 
activities: doing light housework, cooking, making phone calls, taking medication, 
shopping, and taking care of finances. Polypharmacy was defined if participants reported 
taking five types of medications at least once a week.2 Financial difficulties were defined if 
participants reported having had financial difficulties in the past 12 months, having trouble 
making ends meet, receiving means-tested subsidies for health insurance or receiving 
complementary financial support in addition to old-age pension.  
 
Statistical analyses 
We used data from all the participants of the Lc65+ who were still enrolled in the study 
and who participated at the most recent data collection. To assess the cross-sectional 
association between BP and frailty, we restricted the analytical sample to the set of 
participants with complete data for all variables that we selected for our final regression 
models. First, we computed the number of participants (%) with hypertension and 
antihypertensive treatment use, stratified by sex, age and frailty. Second, we analyzed the 
association between BP and frailty by computing mean (SD) systolic BP and mean (SD) 
diastolic BP stratified by sex, age and frailty. Third, we analyzed the association between 
BP and frailty by fitting multivariable linear regression models. For systolic BP and 
diastolic BP, separately, we fitted similar sets of three hierarchical linear regression 
models. In model 1, BP was regressed on frailty status (dummy variable), adjusted for age 
and sex. In model 2, estimates were additionally adjusted for socio-economic 
characteristics (education, Swiss citizenship, financial difficulties, living alone), CVD risk 
factors (hypercholesterolemia, diabetes, history of CVD, smoking), and body mass index 
(BMI). In model 3, estimates were additionally adjusted for antihypertensive medication 
use. We used Stata 14® (Stata Corp, College Station, TX) for all analyses. 
 
Results 
Figure 1 is a flow chart with the number of participants recruited in each sample (C1, C2, 
and C3), the number and reasons for dropouts between recruitment and most recent data 
collection, and the number of participants not considered in the analyses due to missing 
data. Briefly, out of the 4731 individuals initially recruited in 2004, 2009 and 2014, 3651 
individuals participated in the most recent data collection and 3157 had complete data and 
were included in our analyses (see Table S2 in the supplementary digital content files for 
detailed flow charts separately for each of the three samples). There was no major 
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difference in main baseline characteristics between participants with and without missing 
data (see Table S3 in the supplementary digital content files). In the analytical sample, 
slowness was imputed for 60 participants (1.9%). The main reason was a follow-up done 
outside of the study center, where a walking test could not be performed. 
 
Table 1 summarizes baseline characteristics of the participants. Some 2157 were women 
(59.1%) and 1494 were men (40.9%). Mean age of participants was 73.3 (SD: 4.1) years. 
Some 2226 (61.0%) were non-frail, 1243 (34.1%) pre-frail, and 121 (3.3%) frail. Mean BP 
was 135.1/76.3 mmHg (SD 18.5/11.0). Some 1867 (51.1%) reported diagnosed 
hypertension and 1601 (43.9%) reported that they were using antihypertensive medication. 
 
Table 2 shows that the proportion of participants with hypertension tended to be higher in 
men compared to women and increased with age. The proportion of hypertension and use 
of antihypertensive treatment increased across categories of frailty status.  
 
Table 3 shows that mean systolic BP and mean diastolic BP was lower in women than in 
men. While mean systolic BP tended to be higher in higher age categories, mean diastolic 
BP tended to be lower in higher age categories. Mean systolic BP and mean diastolic BP 
were lowest in frail participants and highest in non-frail participants. These differences in 
BP by frailty status were observed consistently across all sex- and age-categories of 
participants.  
 
Table 4 shows that, compared to non-frail participants, mean age- and sex-adjusted 
systolic BP was lower by 2.7 mmHg (95% confidence interval (CI): 1.4 to 4.1) and 6.7 
mmHg (95% CI: 3.2 to 10.3) among pre-frail and frail participants, respectively. Compared 
to non-frail participants, mean age- and sex-adjusted diastolic BP was lower by 1.9 mmHg 
(95% CI: 1.1 to 2.8) and 4.9 mmHg (95% CI: 2.8 to 7.0) in pre-frail and frail participants, 
respectively (model 1). Upon adjustment for socio-economic characteristics, CVD risk 
factors, and BMI, BP remained lower among pre-frail and frail participants compared to 
non-frail (model 2). With additional adjustment for antihypertensive treatment (model 3), 
the difference in BP between non-frail, pre-frail, and frail participants remained similar. 
 
Sensitivity analyses with age included as a simple or quadratic continuous variable did not 
modify our findings. In further sensitivity analyses, we have tested for interactions between 
frailty and sex, age categories, hypercholesterolemia, diabetes, history of cardiovascular 
disease and smoking, respectively. None of these terms was statistically significantly 
associated with BP. Further, including these terms in the regression models did not modify 
our findings. 
 
Discussion 
Using data from a population-based study of older adults, we found that BP was lower 
among pre-frail and even lower among frail compared to non-frail individuals. This 
difference in BP was not explained by the greater use of antihypertensive treatment among 
frail or prefrail older adults. Because low BP could be detrimental among frail older adults, 
these findings raise questions about hypertension management in this population and stress 
the need for additional evidence.  
 
Our results are consistent with other studies having shown that a diagnosis of hypertension 
was more frequent in frail than in non-frail individuals (Table 2), but that measured mean 
BP was lower in frail compared to non-frail individuals (Table 3).9 For instance, in a 
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cohort study by Aprahamian et al. in 2018, the prevalence of hypertension among non-
frail, pre-frail, and frail individuals was 52%, 73%, and 83%, respectively.25 With regard to 
BP, in one recent cross-sectional study by Gijón-Conde et al. conducted among 1047 
participants aged 60 years and over, mean systolic BP was significantly lower by 1.5 
mmHg per additional frailty category as measured by the frailty phenotype.26 Other studies 
have been conducted using the frailty index based on the deficit accumulation model.27 In 
one of these studies using electronic health records from 1.4 million people in the United 
Kingdom9, frailty was associated with low BP. In two other studies using cohort data from 
Canada and Korea, frailty was associated with a U-shaped BP curve.27,28 Our study is 
based on high quality data on BP and frailty and is, to our knowledge, the largest 
population-based study, which investigated the relationship between the frailty phenotype 
and BP. Although the frailty index may have a better ability to discriminate health risk in 
individuals, the frailty phenotype has a better clinical appeal, as the 5 criteria can be 
measured in clinical practice and interventions targeted on these features are possible.29 
This proximity to clinical practice is important in the context of decision-making on 
hypertension management. 
 
Our study has several limitations. First, our sample included a relatively small number of 
frail individuals (n=121; 3.3% of the total sample). Second, although we adjusted our 
regression models for age, sex, history of CVD, BMI, socio-economic characteristics, and 
antihypertensive medication use, there might be some residual confounding. A potential 
confounder could be diet for instance. Third, we rely on self-reported data to some extent, 
e.g., data on hypertension diagnosis and antihypertensive medication use, and this data is 
less reliable than physical measurements. It is possible that some patients reporting 
antihypertensive medication use were actually taking them for other reasons than 
hypertension (e.g., heart failure), leading to a potential overestimation of the proportion of 
hypertension in this population. Furthermore, we had no detailed information on the type 
of antihypertensive medication. The participants were asked whether they use 
antihypertensive medication, without other specifications. Last, our analytical sample may 
be subject to some selection bias. As shown in Figure 1, out of the 4731 participants 
initially recruited, 3157 were finally included in our analyses. Between recruitment and last 
data collection, 381 died and 569 left the study. From those who participated at the most 
recent data collection, 394 were excluded from the analytical sample due to missing data, 
mainly in BP measurements (Table 1). In most cases, these participants could not, or were 
not willing to, attend the physical examination. Since some frail older adults may have not 
participated, it is possible that the proportion of frail individuals in our sample is an 
underestimation of the true proportion in the source population of this age. For the same 
reason, the association between frailty and BP may be systematically different in these 
individuals, because withdrawing from the study may be associated with both frailty and 
low BP. Nevertheless, there was no major difference between participants with or without 
missing data (see Table S3 in the supplementary digital content files).  
  
An important strength of our study is the high quality of data, especially regarding frailty 
and BP. The Lausanne cohort Lc65+ has been specifically designed to assess the 
development and determinants of frailty and, hence, frailty status has been carefully 
measured. Both BP and frailty have been measured for study purposes at the study center 
by trained study research assistants following a standardized procedure kept identical 
across years.16 BP has been measured three times at one visit, although not using home or 
ambulatory BP monitoring, but nonetheless in line with an ideal clinical setting, with 
participants in a resting state and sitting in a recommended posture.4,30 Another strength of 
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our study is that we used the frailty phenotype, and not the frailty index; the frailty 
phenotype, although less discriminative, is more appealing for clinical use.29 In fine, the 
external validity of our findings may be challenged by selection bias and reduced 
representativeness, our results have a high internal validity due to reliable measurement 
methods for BP and frailty.  
 
Our results suggest that an association between frailty and low BP exists, although the 
nature of this relationship stays unclear.1 According to Hernán and Robins31, there are 
three structural reasons, why two variables may be associated: i.e. one variable is the cause 
of the other, both variables share a common cause, or the association was analyzed while 
conditioning on a common effect of both variables. Figure 2 summarizes some hypotheses 
related to the previously mentioned reaons for an association. First, low BP may cause 
frailty (I). For instance, Muller et al. speculated that low BP causes frailty in older 
individuals because, in a physiologically vulnerable state, low BP may reduce blood 
perfusion and oxygenation of vital organs, and, hence, lead to damage, loss of 
functionality, and a state of frailty.32 Second, frailty may cause low BP (II). Indeed, a state 
of frailty is associated with a weakening of several physiological functions, including the 
ability of the heart to sustain a given level of BP. Third, frailty may cause low BP, which 
in turn could exacerbate frailty (III). Forth, the relationship might be due to confounding 
(IV). For instance, poor nutrition or some debilitating diseases can cause both frailty and a 
low BP.9 The key is that confounding should be correctly assessed, using subject matter 
knowledge and integrating reflections on temporality, with some variables, for instance 
antihypertensive medications, acting as confounders at some time points and as mediators 
at some other time points. For these type of analyses, longitudinal data are needed, 
allowing the investigation of the effect of certain BP levels, but also of life long exposure 
to hypertension or to dynamic changes in BP as in end-of-life decline in BP.9,33 Finally, we 
cannot exclude the possibility that selection bias explains part of our findings. Further 
studies are needed to understand the possible mechanisms at play. 
 
Currently, hypertension management in older adults is still highly debated. This is well 
illustrated by discordances across current major hypertension management guidelines. 
Recent North-American guidelines recommend treating older adults to systolic BP targets 
of 130 mmHg, irrespective of older age or frailty status.4 These recommendations have 
triggered criticism for downplaying and ignoring risks associated to low BP, such as falls, 
and physical and mental decline pinpointed in population-based cohort studies.10,34 More 
conservative, European guidelines published in 2018 emphasize that BP thresholds and BP 
treatment targets should be set accounting for biological age, and that frailty, 
independence, and tolerability of treatment have to be considered in the decision on how to 
treat a patient. According to the latter, older age, however, is not an argument for denying 
treatment per se. These guidelines recommend to lower systolic BP in older adults below 
140 mmHg but not below 130 mmHg.5  
 
Key in the debate is to understand the relationship between BP and frailty. In addition to 
being associated with low BP, frailty has been shown to be associated with a higher risk 
for orthostatic hypotension35,36 while the link with cardiovascular disease risk remains 
unclear.12,32,37 Since frail persons with multimorbidity and polypharmacy are highly 
prevalent and represent an ever-growing population in our ageing society, there is an 
urgent need to clarify this relationship to enable health care providers to adequately 
manage hypertension. While opinions diverge, with some authors speculating that lowering 
BP in frail patients is harmful and others who consider frailty as a risk factor for 
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undertreatment, there is a need for scientific evidence in frail participants.4,5,38 An analysis 
using longitudinal data and aiming for causal inference may help understanding the 
relationship between BP and frailty and give an indication on how to treat frail older adults 
for hypertension.  
 
In conclusion, our results show that BP and frailty occur together in older adults, and raise 
the question on why they are related and on what is the impact of this relationship on the 
management of hypertension in older adults.  
Accepted author’s manuscript. Published in final edited form as: Journal of Clinical 
Hypertension. 2019. Publisher DOI: https://doi.org/10.1111/jch.13722  
 
 
 
References 
1. Anker D, Santos-Eggimann B, Santschi V, et al. Screening and treatment of 
hypertension in older adults: less is more?  Public health reviews. 2018;39:26. 
2. Benetos A, Rossignol P, Cherubini A, et al. Polypharmacy in the Aging Patient: 
Management of Hypertension in Octogenarians. Jama. 2015;314(2):170-180. 
3. Musini VM, Tejani AM, Bassett K, Wright JM. Pharmacotherapy for hypertension 
in the elderly. The Cochrane database of systematic reviews. 2009(4):Cd000028. 
4. Whelton PK, Carey RM, Aronow WS, et al. 2017 
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline 
for the Prevention, Detection, Evaluation, and Management of High Blood Pressure 
in Adults: Executive Summary: A Report of the American College of 
Cardiology/American Heart Association Task Force on Clinical Practice 
Guidelines. Hypertension (Dallas, Tex : 1979). 2018;71(6):1269-1324. 
5. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH 2018 ESC/ESH 
Guidelines for the management of arterial hypertension. European heart journal. 
2018;39(33):3021-3104. 
6. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. The Cochrane 
database of systematic reviews. 2018;4:Cd001841. 
7. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 
years of age or older. The New England journal of medicine. 2008;358(18):1887-
1898. 
8. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs Standard Blood 
Pressure Control and Cardiovascular Disease Outcomes in Adults Aged >/=75 
Years: A Randomized Clinical Trial. Jama. 2016;315(24):2673-2682. 
9. Ravindrarajah R, Hazra NC, Hamada S, et al. Systolic Blood Pressure Trajectory, 
Frailty, and All-Cause Mortality >80 Years of Age: Cohort Study Using Electronic 
Health Records. Circulation. 2017;135(24):2357-2368. 
10. Sabayan B, Oleksik AM, Maier AB, et al. High blood pressure and resilience to 
physical and cognitive decline in the oldest old: the Leiden 85-plus Study. Journal 
of the American Geriatrics Society. 2012;60(11):2014-2019. 
11. Streit S, Poortvliet RKE, Gussekloo J. Lower blood pressure during 
antihypertensive treatment is associated with higher all-cause mortality and 
accelerated cognitive decline in the oldest-old-data from the Leiden 85-plus Study. 
Age and ageing. 2018. 
12. Odden MC, Peralta CA, Haan MN, Covinsky KE. Rethinking the association of 
high blood pressure with mortality in elderly adults: the impact of frailty. Archives 
of internal medicine. 2012;172(15):1162-1168. 
13. van Hateren KJ, Hendriks SH, Groenier KH, et al. Frailty and the relationship 
between blood pressure and mortality in elderly patients with type 2 diabetes 
(Zwolle Outpatient Diabetes project Integrating Available Care-34). Journal of 
hypertension. 2015;33(6):1162-1166. 
14. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. 
Lancet (London, England). 2013;381(9868):752-762. 
15. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the 
concepts of disability, frailty, and comorbidity: implications for improved targeting 
and care. The journals of gerontology Series A, Biological sciences and medical 
sciences. 2004;59(3):255-263. 
16. Santos-Eggimann B, Karmaniola A, Seematter-Bagnoud L, et al. The Lausanne 
cohort Lc65+: a population-based prospective study of the manifestations, 
determinants and outcomes of frailty. BMC geriatrics. 2008;8:20. 
Accepted author’s manuscript. Published in final edited form as: Journal of Clinical 
Hypertension. 2019. Publisher DOI: https://doi.org/10.1111/jch.13722  
 
 
 
17. Macklai NS, Spagnoli J, Junod J, Santos-Eggimann B. Prospective association of 
the SHARE-operationalized frailty phenotype with adverse health outcomes: 
evidence from 60+ community-dwelling Europeans living in 11 countries. BMC 
geriatrics. 2013;13:3. 
18. The Lc65+ cohort. [Internet]. Available from https://lc65plus.iumsp.ch/. Accessed 
08.04.2019. 
19. El Assaad MA, Topouchian JA, Darne BM, Asmar RG. Validation of the Omron 
HEM-907 device for blood pressure measurement. Blood pressure monitoring. 
2002;7(4):237-241. 
20. White WB, Anwar YA. Evaluation of the overall efficacy of the Omron office 
digital blood pressure HEM-907 monitor in adults. Blood pressure monitoring. 
2001;6(2):107-110. 
21. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a 
phenotype. The journals of gerontology Series A, Biological sciences and medical 
sciences. 2001;56(3):M146-156. 
22. Mathiowetz V, Vizenor L, Melander D. Comparison of Baseline Instruments to the 
Jamar Dynamometer and the B&L Engineering Pinch Gauge. OTJR Occupation 
Participation Health 2000;20(3):147-162. 
23. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the 
aged. The index of ADL: a standardized measure of biological and psychological 
function Jama. 1963;185:914-919. 
24. Lawton MP, Brody EM. Assessment of older people: self-maintaining and 
instrumental activities of daily living. The Gerontologist. 1969;9(3):179-186. 
25. Aprahamian I, Sassaki E, Dos Santos MF, et al. Hypertension and frailty in older 
adults. Journal of clinical hypertension (Greenwich, Conn). 2018;20(1):186-192. 
26. Gijon-Conde T, Graciani A, Lopez-Garcia E, et al. Frailty, Disability, and 
Ambulatory Blood Pressure in Older Adults. Journal of the American Medical 
Directors Association. 2018;19(5):433-438. 
27. Rockwood K, Mitnitski A. Frailty defined by deficit accumulation and geriatric 
medicine defined by frailty. Clin Geriatr Med. 2011;27(1):17-26. 
28. Kang MG, Kim SW, Yoon SJ, Choi JY, Kim KI, Kim CH. Association between 
Frailty and Hypertension Prevalence, Treatment, and Control in the Elderly Korean 
Population. Sci Rep. 2017;7(1):7542. 
29. Kim DH, Schneeweiss S. Measuring frailty using claims data for 
pharmacoepidemiologic studies of mortality in older adults: evidence and 
recommendations. Pharmacoepidemiology and drug safety. 2014;23(9):891-901. 
30. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the 
management of arterial hypertension. European heart journal. 2018;39(33):3021-
3104. 
31. Hernán MA, Robins JM. Causal Inference. Boca Raton: Chapman & Hall/CRC; 
2019, forthcoming. 
32. Muller M, Smulders YM, de Leeuw PW, Stehouwer CD. Treatment of 
hypertension in the oldest old: a critical role for frailty? Hypertension (Dallas, Tex : 
1979). 2014;63(3):433-441. 
33. Delgado J, Bowman K, Ble A, et al. Blood Pressure Trajectories in the 20 Years 
Before Death. JAMA Intern Med. 2018;178(1):93-99. 
34. Husten L. Search Results for: SPRINT [Internet] CardioBrief. 2017. Available 
from http://www.cardiobrief.org/?s=SPRINT Accessed 08.04.2019. 
Accepted author’s manuscript. Published in final edited form as: Journal of Clinical 
Hypertension. 2019. Publisher DOI: https://doi.org/10.1111/jch.13722  
 
 
 
35. Rockwood MR, Howlett SE, Rockwood K. Orthostatic hypotension (OH) and 
mortality in relation to age, blood pressure and frailty. Arch Gerontol Geriatr. 
2012;54(3):e255-260. 
36. O'Connell MD, Savva GM, Fan CW, Kenny RA. Orthostatic hypotension, 
orthostatic intolerance and frailty: The Irish Longitudinal Study on Aging-TILDA. 
Arch Gerontol Geriatr. 2015;60(3):507-513. 
37. Newman AB, Gottdiener JS, McBurnie MA, et al. Associations of subclinical 
cardiovascular disease with frailty. The journals of gerontology Series A, Biological 
sciences and medical sciences. 2001;56(3):M158-166. 
38. Joyce E. Frailty and cardiovascular disease: A two-way street? Cleveland Clinic 
journal of medicine. 2018;85(1):65-68. 
39. The Lc65+ cohort. Sampling. [Internet]. Available from 
https://lc65plus.iumsp.ch/en/content/sampling. Accessed 08.04.2019. 
 
 
 
13 
 
 
 
Funding: 
None. 
 
The Lc65+ study has been supported by University of Lausanne Hospital Centre; University 
of Lausanne Department of Ambulatory Care and Community Medicine; Canton de Vaud 
Department of Public Health; City of Lausanne; Loterie Romande [research grants 2006-2008 
and 2018-2019]; Lausanne University Faculty of Biology and Medicine [multidisciplinary 
research grant 2006]; Swiss National Foundation for Scientific Research [grant 3247B0-
120795/1]; and Fondation Médecine Sociale et Préventive, Lausanne. The sponsors had no 
role in the design, execution, analysis and interpretation of data, or writing of the study. 
 
Conflict of interest:  
The authors report no conflict of interest. 
 
Acknowledgments: 
Not Applicable. 
 
14 
 
 
 
Table 1. Baseline characteristics of participants at most recent data collection in the Lausanne 
cohort Lc65+.  
Characteristics of participants   n (%) 
Total N 
 
3651 
Sex Women 2157 (59.1)  
Men 1494 (40.9)  
Missing 0 (0.0) 
Age [years], mean (SD) 
 
73.3 (4.1)  
Missing, n(%) 0 (0.0) 
Socioeconomic characteristics Living alone 2364 (64.8)  
Swiss citizenship 3223 (88.3)  
Education 
 
 
  Basic compulsory 645 (17.7)  
  Apprenticeship 1410 (38.6)  
  High school 902 (24.7)  
  University 675 (18.5)  
Financial difficulties 938 (25.7)  
Missing in at least one variable in 
socioeconomic characteristics 
419 (11.5) 
Frailty status Non-frail 2226 (61.0)  
Pre-frail 1243 (34.1)  
Frail 121 (3.3)  
Missing 61 (1.7) 
BP [mmHg], mean (SD) Systolic BP 135.1 (18.5)  
Diastolic BP 76.3 (11.0)  
Missing, n(%) 441 (12.1) 
Hypertension Hypertension treatment or 
diagnosis (self-reported) 
1867 (51.1) 
 Missing 37 (1.0) 
 Hypertension treatment (self-
reported) 
1601 (43.9) 
 Missing 51 (1.4) 
 BP≥ 140/90 mmHg (measured) 1248 (34.2) 
 Missing 441 (12.1) 
 BP≥140/90 mmHg (measured) or 
antihypertensive medication use 
(self-reported) 
2243 (61.4) 
 
Missing 248 (6.8) 
Other CVD risk factors Hypercholesterolemia 1298 (35.6)  
Diabetes 417 (11.4)  
History of CVD 945 (25.9)  
Smoking  
 
 
  Current smoker 604 (16.5)  
  Former smoker 1468 (40.2)  
  Never smoker 1553 (42.5)  
Missing in at least one variable in 
other CVD risk factors 
79 (2.2) 
BMI [kg/m2], mean (SD) 
 
26.9 (4.8) 
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Missing, n(%) 442 (12.1) 
BMI category Underweight (BMI < 18.5 kg/m2) 48 (1.3)  
Normal (BMI 18.5-24.9 kg/m2) 1144 (31.3)  
Overweight (BMI 25-29.9 kg/m2) 1305 (35.7)  
Obese (BMI ≥ 30 kg/m2) 712 (19.5)  
Missing 442 (12.1) 
Number of chronic diseases 0 746 (20.4)  
1 1092 (29.9)  
≥ 2 1813 (49.7) 
Functional status Help received with BADLs 
 
 
  No difficulties 2920 (80.0)  
  Difficulties 375 (10.3)  
  Difficulties and receiving help 113 (3.1)  
  Missing 243 (6.7)  
Help received with IADLs 
 
 
  No difficulties 2773 (76.0)  
  Difficulties 321 (8.8)  
  Difficulties and receiving help 373 (10.2)  
  Missing 184 (5.0) 
Polypharmacy 
 
751 (20.6) 
  Missing 435 (11.9) 
Values are numbers (%) unless indicated otherwise. n, number of participants; SD, standard 
deviation; BP, blood pressure; CVD, cardiovascular disease; BADL, basic activities of daily 
living; IADL, instrumental activities of daily living; Polypharmacy: self-reported use of ≥ 5 
medication at least once a week.
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Table 2. Number (%) of participants with hypertension, and using antihypertensive medication, stratified by sex, age and frailty status.  
  Men 
(n=1299) 
       Women 
(n=1858) 
       Men and 
women   
67-70 
years   
71-75 
years  
76-80 
years 
All age 
categories 
 67-70 
years   
71-75 
years  
76-80 
years 
All age 
categories 
 All age 
categories 
Diagnosed 
with or 
treated for 
hypertension 
non-frail 164 (50.1) 118 (51.5) 165 (56.5) 447 (52.7)  134 (32.5) 124 (38.5) 179 (46.9) 437 (39.2)  884 (45.0) 
 
pre-frail 81 (66.4) 79 (62.7) 112 (66.7) 272 (65.4)  86 (49.1) 93 (52.0) 191 (60.4) 370 (55.2)  642 (59.1)  
frail 7 (70.0) 5 (83.3) 18 (94.7) 30 (85.7)  12 (70.6) 11 (52.4) 20 (58.8) 43 (59.7)  73 (68.2) 
Treated for 
hypertension 
non-frail 137 (41.9) 104 (45.4) 150 (51.4) 391 (46.1)  110 (26.7) 106 (32.9) 162 (42.4) 378 (33.9)  769 (39.2) 
 
pre-frail 71 (58.2) 71 (56.3) 99 (58.9) 241 (57.9)  68 (38.9) 79 (44.1) 172 (54.4) 319 (47.6)  560 (51.6) 
  frail 6 (60.0) 4 (66.7) 15 (79.0) 25 (71.4)  11 (64.7) 7 (33.3) 13 (38.2) 31 (43.1)  56 (52.3) 
The analytical sample consisted of 3157 participants with complete data for all variables. n, number of participants. 
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Table 3. Mean (SD) systolic and diastolic BP, stratified by sex, age and frailty status.  
 
  
  Men  
(n=1299) 
       Women  
(n=1858) 
    
  
 Men and 
women   
67-70 
years   
71-75 
years  
76-80 
years 
All age 
categories 
 67-70 
years   
71-75 
years  
76-80 
years 
All age 
categories 
 All age 
categories 
Systoli
c BP 
[mmHg
] 
non-
frail 139.1 
(16.0) 
138.9 
(17.6) 
140.2 
(17.7) 
139.4 
(17.0) 
 
131.2 
(18.9) 
133.0 
(17.8) 
137.4 
(19.7) 
133.9 
(19.1) 
 
136.3 
(18.4) 
 
pre-
frail 
139.2 
(19.3) 
136.0 
(15.6) 
136.8 
(18.3) 
137.3 
(17.9) 
 130.0 
(19.3) 
129.1 
(16.5) 
133.1 
(18.1) 
131.2 
(18.1) 
 133.4 
(18.2)  
frail 134.1 
(18.3) 
130.8 
(18.7) 
131.4 
(23.8) 
132.1 
(21.0) 
 126.8 
(22.5) 
128.5 
(12.9) 
128.4 
(16.6) 
128.1 
(17.0) 
 129.1 
(18.5) 
             
Diastol
ic BP 
[mmHg
] 
non-
frail 80.4 
(10.8) 
77.7 
(10.5) 
76.5 
(10.8) 
78.3 
(10.9) 
 
77.4 
(10.6) 
75.8 
(9.9) 
76.1 
(10.6) 
76.5 
(10.5) 
 
77.3 
(10.7) 
 
pre-
frail 
77.5 
(11.1) 
75.1 
(9.8) 
74.4 
(11.1) 
75.6 
(10.8) 
 77.0 
(12.0) 
73.5 
(10.5) 
74.0 
(11.0) 
74.7 
(11.2) 
 74.9 
(11.1) 
  frail 77.3 
(10.8) 
73.9 
(16.7) 
64.6 
(13.0) 
69.8 
(14.0) 
 73.6 
(14.6) 
75.0 
(12.6) 
71.2 
(10.9) 
72.9 
(12.3) 
 71.6 
(12.8) 
The analytical sample consisted of 3157 participants with complete data for all variables. n, number of participants; SD, standard deviation; 
BP, blood pressure.
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Table 4. Linear regression models of frailty upon systolic blood pressure (BP), and of frailty 
upon diastolic BP.  
  Model 1 Model 2 Model 3 
  Difference in BP 
(95%CI) 
[mmHg] 
Difference in BP 
(95%CI) 
[mmHg] 
Difference in BP 
(95%CI) 
[mmHg] 
Systolic BP 
 
 
 
Frailty status    
Non-frail ref ref ref 
Pre-frail -2.7 (-4.1 to -1.4) -2.6 (-3.9 to -1.2) -2.8 (-4.2 to -1.5) 
Frail -6.7 (-10.3 to -3.2) -6.1 (-9.6 to -2.5) -6.2 (-9.8 to -2.7) 
Age    
67-70 years  ref ref ref 
71-75 years 0.1 (-1.5 to 1.7) 0.5 (-1.2 to 2.2) 0.4 (-1.3 to 2.0) 
76-80 years 2.9 (1.4 to 4.4) 3.5 (1.8 to 5.2) 3.0 (1.3 to 4.7) 
Sex    
Men ref ref ref 
Women -5.7 (-7.0 to -4.4) -6.8 (-8.2 to -5.4) -6.6 (-8.0 to -5.2) 
BMI category    
Underweight  - 2.2 (-3.1 to 7.4) 2.5 (-2.7 to 7.7) 
Normal weight - ref ref 
Overweight  - 3.0 (1.5 to 4.4) 2.4 (0.9 to 3.9) 
Obese  - 1.6 (-0.2 to 3.4) 0.5 (-1.3 to 2.3) 
Antihypertensive treatment     
No  - - ref 
Yes - - 4.4 (3.0 to 5.8) 
Diastolic BP 
 
 
 
Frailty status    
Non-frail ref ref ref 
Pre-frail -1.9 (-2.8 to -1.1) -1.8 (-2.6 to -1.0) -1.8 (-2.7 to -1.0) 
Frail -4.9 (-7.0 to -2.8) -4.4 (-6.5 to -2.3) -4.4 (-6.5 to -2.3) 
Age    
67-70 years  ref ref ref 
71-75 years -2.3 (-3.2 to -1.3) -1.7 (-2.7 to -0.7) -1.8 (-2.8 to -0.8) 
76-80 years -2.7 (-3.6 to -1.8) -1.7 (-2.7 to -0.7) -1.8 (-2.8 to -0.8) 
Sex    
Men ref ref ref 
Women -1.3 (-2.1 to -0.5) -2.0 (-2.9 to -1.2) -2.0 (-2.8 to -1.2) 
BMI category    
Underweight  - 0.4 (-2.7 to 3.4) 0.4 (-2.7 to 3.5) 
Normal weight - ref ref 
Overweight  - 2.8 (1.9 to 3.7) 2.8 (1.9 to 3.6) 
Obese - 3.7 (2.6 to 4.7) 3.6 (2.5 to 4.7) 
Antihypertensive treatment     
No  - - ref 
Yes - - 0.3 (-0.5 to 1.1) 
Coefficients are differences in mean blood pressure (BP) as compared to the reference 
category (ref). The analytical sample consisted of 3157 participants with complete data for all 
variables. Model 1: adjusted for age and sex. Model 2: Model 1 + adjusted for socio-
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economic characteristics (education, Swiss citizenship, financial difficulties, living alone), 
CVD risk factors (hypercholesterolemia, diabetes, history of CVD, smoking), and body mass 
index (BMI); Model 3: Model 2 + adjusted for antihypertensive medication use. 95% CI, 95% 
confidence interval. 
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Figure 1. Flow chart of individuals targeted, invited, and finally included in our analyses.  
 
C1, sample 1 with a recruitment having started in 2004; C2, sample 2 with a recruitment 
having started in 2009; C3, sample 3 with a recruitment having started in 2014; N, total 
number of participants in the Lc65+; n, number of individuals.39 
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Figure 2. Potential causal relationships explaining the association between blood pressure 
(BP) and frailty (F).  
 
C, confounding factor. 
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Table S1. Detailed information about data collection for each variable.  
Variables Time point of 
data 
collection 
Data collection 
method 
Data output 
Sex Baseline Population register Binary (male / female) 
Age  Baseline Population register 
and date of data 
collection 
Continuous 
Socioeconomic 
characteristics 
   
Living alone Most recent 
data collection 
Self-reported Binary (yes / no) 
Swiss citizenship Baseline Self-reported Binary (yes / no) 
Education Baseline Self-reported Categorical (basic compulsory / 
apprenticeship, high school / 
university) 
Financial difficulties Most recent 
data collection 
Self-reported Binary (yes / no) 
Frailty status Most recent 
data collection 
Derived from 
variables below 
 
Categorical (non-frail / pre-frail / 
frail) 
Weakness (grip 
strength) 
Most recent 
data collection 
Measured Binary (yes / no)  
Low grip strength was defined 
according to CHS gender and 
body mass index specific cut-off 
value 
Slowness (walking 
speed) 
Most recent 
data collection 
Measured 
(slowness was 
imputed based on 
judgement of study 
research assistant in 
some cases) 
Binary (yes / no) 
Low walking speed was defined 
according to CHS gender and 
body mass index specific cut-off 
value 
Feeling of exhaustion Most recent 
data collection 
Self-reported Binary (yes / no) 
The participant responds “a lot” to 
“did you have feelings of 
generalized weakness, 
weariness, lack of energy in the 
last four weeks? 
Shrinking 
(unvoluntary weight 
loss) 
Most recent 
data collection 
Self-reported Binary (yes / no) 
The participant reports any 
unintentional weight loss in prior 
year 
Low activity (physical 
activity) 
Most recent 
data collection 
Self-reported Binary (yes / no) 
The participant reports: less than 
20 minutes of sport activity once a 
week and less than 30 cumulated 
minutes walk per day 3 times a 
week and avoidance of stairs 
climbing or light loads carrying in 
daily activities 
Systolic and diastolic 
BP  
Most recent 
data collection 
Measured Continuous 
Hypertension treatment 
or diagnosis 
Baseline  Self-reported Binary (yes / no) 
 
 Most recent 
data collection 
Self-reported Binary (yes / no) 
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Hypertension treatment Most recent 
data collection 
Self-reported Binary (yes / no) 
 
Other CVD risk factors    
Hypercholesterolemia  Most recent 
data collection 
Self-reported Binary (yes / no) 
Diabetes  Most recent 
data collection 
Self-reported Binary (yes / no) 
History of CVD  Baseline  Self-reported Binary (yes / no) 
 Most recent 
data collection 
Self-reported  
Smoking  Most recent 
data collection 
Self-reported Categorical (current smoker / 
former smoker / never smoker) 
BMI Most recent 
data collection 
Measured 
(Weight and height 
were imputed based 
on self-reports in 
some cases) 
Continuous 
Number of chronic 
diseases 
Most recent 
data collection 
Self-reported Categorical (0 / 1 / ≥ 2) 
Functional status 
(BADL and IADL) 
Most recent 
data collection 
Self-reported Categorical (no difficulties / 
difficulties for at least one activity / 
difficulties for at least one activity 
+ need for assistance) 
 
Polypharmacy Most recent 
data collection 
Self-reported Binary (yes/no) 
Baseline information was collected in 2004/05, 2009/10, and 2014/15 for sample 1, 2, and 3, 
respectively. Most recent data collection was in 2014, 2016 and 2015 for sample 1, 2, and 3, 
respectively. BP, blood pressure; CVD, cardiovascular disease; BMI, body mass index; 
BADL, basic activity of daily living; IADL, instrumental activity of daily living; CHS, 
Cardiovascular Health Study.  
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Table S2. Detailed overview for each sample of number of participants (%) at recruitment, at most recent data collection and included in our 
analytical sample (C1, C2, and C3) with number and reasons for dropouts and exclusions.    
C1  C2  C3  Total 
  
  
N % N % N % N % related to 
participants at 
recruitment 
% related to 
participants at most 
recent data 
collection 
Number of 
participants at 
recruitment 
Total 1564 100% 1489 100% 1678 100% 4731 100% 
 
Permanent drop-outs 
from the study 
Deceased 234 15% 133 9% 14 1% 381 8% 
 
 
Quit study 248 16% 206 14% 115 7% 569 12% 
 
 
Other 28 2% 33 2% 69 4% 130 3% 
 
Number of 
participants at most 
recent data collection 
Total 1054 67% 1117 75% 1480 88% 3651 77% 100,0% 
 
Reasons for missing 
data at most recent 
data collection 
Only questionnaire 116  127  151  394 
 
10,8% 
 
 
Only physical 
examination 
3  2  1  6 
 
0,2% 
  
Partial examination 2  1  3  6 
 
0,2% 
  
Proxy 25  12  1  38 
 
1,0% 
  
Missings for 
individual variables 
27  10  13  50 
 
1,4% 
 
Participants with 
complete data for all 
variables included in 
regression models 
Total 881 56% 965 65% 1311 78% 3157 67% 86,5% 
C1, sample 1; C2, sample 2; C3, sample 3 
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Table S3. Differences in main baseline characteristics between participants with complete 
data for all variables and participants with missing data at most recent data collection in the 
Lausanne cohort Lc65+.  
Characteristics of 
participants 
  Analytical sample Excluded from the 
analytical sample 
N 
 
3157 494 
Sex Women 1858 (58,9%) 299 (60,5%)  
Men 1299 (41,1%) 195 (39,5%)  
Missing 
 
0 
Age [years], mean (SD) 
 
73,2 (4,0) 74,0 (4,0)  
Missing 
 
0 
Frailty status Non-frail 1964 (62,2%) 262 (60,5%)  
Pre-frail 1086 (34,4%) 157 (36,3%)  
Frail 107 (3,4%) 14 (3,2%)  
Missing 
 
61 
BP [mmHg], mean (SD) Systolic BP 135,1 (18,4) 133,4 (21,9)  
Diastolic BP 76,3 (11,0) 74,7 (13,1)  
Missing 
 
441 
Hypertension treatment 
or diagnosis 
 
1599 (50,6%) 268 (58,6%) 
 
Missing 
 
37 
Hypertension treatment 
 
1385 (43,9%) 216 (48,8%) 
  Missing   51 
Values are numbers (%) unless indicated otherwise. n, number of participants; SD, standard 
deviation; BP, blood pressure.  
 
